Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

NCT00310674 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Prevention of Meningococcal Infection

Interventions

BIOLOGICAL: Meningococcal C Conjugate Vaccine

Sponsor

Novartis

Collaborators

[object Object]